Tompkins Financial Corp Purchases 145 Shares of Thermo Fisher Scientific Inc. $TMO

Tompkins Financial Corp lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 9.3% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,707 shares of the medical research company’s stock after buying an additional 145 shares during the period. Tompkins Financial Corp’s holdings in Thermo Fisher Scientific were worth $692,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Mondrian Investment Partners LTD grew its holdings in shares of Thermo Fisher Scientific by 146.1% during the 1st quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company’s stock valued at $106,738,000 after purchasing an additional 127,357 shares during the last quarter. Advisors Capital Management LLC lifted its stake in Thermo Fisher Scientific by 6.7% in the first quarter. Advisors Capital Management LLC now owns 127,011 shares of the medical research company’s stock worth $63,201,000 after acquiring an additional 7,967 shares during the period. Foresight Group Ltd Liability Partnership grew its holdings in shares of Thermo Fisher Scientific by 3,242.7% during the 1st quarter. Foresight Group Ltd Liability Partnership now owns 58,497 shares of the medical research company’s stock worth $29,113,000 after acquiring an additional 56,747 shares during the period. Ilmarinen Mutual Pension Insurance Co increased its stake in shares of Thermo Fisher Scientific by 5.3% in the 1st quarter. Ilmarinen Mutual Pension Insurance Co now owns 67,300 shares of the medical research company’s stock worth $33,488,000 after acquiring an additional 3,400 shares in the last quarter. Finally, GAMMA Investing LLC lifted its holdings in shares of Thermo Fisher Scientific by 22.0% during the first quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company’s stock valued at $2,419,000 after purchasing an additional 877 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Trading Down 1.7%

Shares of Thermo Fisher Scientific stock opened at $472.33 on Thursday. The stock has a 50 day moving average of $470.12 and a 200 day moving average of $450.56. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $623.77. The firm has a market capitalization of $178.36 billion, a price-to-earnings ratio of 27.32, a PEG ratio of 2.57 and a beta of 0.75.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same period in the prior year, the firm earned $5.37 earnings per share. The business’s revenue for the quarter was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 9.95%.

Insider Buying and Selling

In related news, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares of the company’s stock, valued at $10,735,712.66. This trade represents a 1.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction on Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares of the company’s stock, valued at $1,142,408.97. This trade represents a 14.24% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 30,066 shares of company stock valued at $14,182,963 over the last three months. 0.33% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on TMO. Royal Bank Of Canada set a $561.00 target price on shares of Thermo Fisher Scientific and gave the stock an “outperform” rating in a research note on Tuesday, September 2nd. Wells Fargo & Company reduced their price target on Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating for the company in a research report on Thursday, July 24th. Raymond James Financial restated an “outperform” rating and issued a $535.00 price objective (up from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Barclays upgraded Thermo Fisher Scientific from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $490.00 to $550.00 in a research report on Thursday, September 11th. Finally, HSBC reaffirmed a “hold” rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Seventeen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average price target of $592.24.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.